Ali A. Alattar
University of California, San Diego
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ali A. Alattar.
Journal of Neurosurgery | 2017
Ali A. Alattar; Michael G. Brandel; Brian R. Hirshman; Xuezhi Dong; Kate T. Carroll; Mir Amaan Ali; Bob S. Carter; Clark C. Chen
OBJECTIVE The available evidence suggests that the clinical benefits of extended resection are limited for chemosensitive tumors, such as primary CNS lymphoma. Oligodendroglioma is generally believed to be more sensitive to chemotherapy than astrocytoma of comparable grades. In this study the authors compare the survival benefit of gross-total resection (GTR) in patients with oligodendroglioma relative to patients with astrocytoma. METHODS Using the Surveillance, Epidemiology, and End Results (SEER) Program (1999-2010) database, the authors identified 2378 patients with WHO Grade II oligodendroglioma (O2 group) and 1028 patients with WHO Grade III oligodendroglioma (O3 group). Resection was defined as GTR, subtotal resection, biopsy only, or no resection. Kaplan-Meier and multivariate Cox regression survival analyses were used to assess survival with respect to extent of resection. RESULTS Cox multivariate analysis revealed that the hazard of dying from O2 and O3 was comparable between patients who underwent biopsy only and GTR (O2: hazard ratio [HR] 1.06, 95% confidence interval [CI] 0.73-1.53; O3: HR 1.18, 95% CI 0.80-1.72). A comprehensive search of the published literature identified 8 articles without compelling evidence that GTR is associated with improved overall survival in patients with oligodendroglioma. CONCLUSIONS This SEER-based analysis and review of the literature suggest that GTR is not associated with improved survival in patients with oligodendroglioma. This finding contrasts with the documented association between GTR and overall survival in anaplastic astrocytoma and glioblastoma. The authors suggest that this difference may reflect the sensitivity of oligodendroglioma to chemotherapy as compared with astrocytomas.
Neurosurgery | 2018
Ali A. Alattar; Brian R. Hirshman; Brandon A. McCutcheon; Clark C. Chen; Thomas H. Alexander; Jeffrey P. Harris; Bob S. Carter
BACKGROUND Cerebrospinal fluid (CSF) leak is a well-recognized complication after surgical resection of vestibular schwannomas and is associated with a number of secondary complications, including readmission and meningitis. OBJECTIVE To identify risk factors for and timing of 30-d readmission with CSF leak. METHODS Patients who had undergone surgical resection of a vestibular schwannoma from 1995 to 2010 were identified in the California Office of Statewide Health Planning and Development database. The most common admission diagnoses were identified by International Classification of Disease, ninth Revision, diagnosis codes, and predictors of readmission with CSF leak were determined using logistic regression. RESULTS A total of 6820 patients were identified. CSF leak, though a relatively uncommon cause of admission after discharge (3.52% of all patients), was implicated in nearly half of 490 readmissions (48.98%). Significant independent predictors of readmission with CSF leak were male sex (odds ratio [OR] 1.72, 95% confidence interval [CI] 1.32-2.25), first admission at a teaching hospital (OR 3.32, 95% CI 1.06-10.39), CSF leak during first admission (OR 1.84, 95% CI 1.33-2.55), obesity during first admission (OR 2.10, 95% CI 1.20-3.66), and case volume of first admission hospital (OR of log case volume 0.82, 95% CI 0.70-0.95). Median time to readmission was 6 d from hospital discharge. CONCLUSION This study has quantified CSF leak as an important contributor to nearly half of all readmissions following vestibular schwannoma surgery. We propose that surgeons should focus on technical factors that may reduce CSF leakage and take advantage of potential screening strategies for the detection of CSF leakage prior to first admission discharge.
World Neurosurgery | 2017
Kate T. Carroll; Brian R. Hirshman; Mir Amaan Ali; Ali A. Alattar; Michael G. Brandel; Bryson Lochte; Tyler Lanman; Bob S. Carter; Clark C. Chen
Journal of Neuro-oncology | 2017
Michael G. Brandel; Ali A. Alattar; Brian R. Hirshman; Xuezhi Dong; Kate T. Carroll; Mir Amaan Ali; Bob S. Carter; Clark C. Chen
World Neurosurgery | 2018
Ali A. Alattar; Kate T. Carroll; Alex K. Bryant; Brian R. Hirshman; Rushikesh Joshi; Bob S. Carter; Olivier Harismendy; Clark C. Chen
World Neurosurgery | 2018
Kate T. Carroll; Alex K. Bryant; Brian R. Hirshman; Ali A. Alattar; Rushikesh Joshi; Brandon C Gabel; Bob S. Carter; Olivier Harismendy; Florin Vaida; Clark C. Chen
World Neurosurgery | 2018
Rushikesh Joshi; Brian R. Hirshman; Mir Amaan Ali; Ali A. Alattar; Kate T. Carroll; Osamu Nagano; Hitoshi Aiyama; Toru Serizawa; Masaaki Yamamoto; Clark C. Chen
World Neurosurgery | 2018
Ali A. Alattar; Kate T. Carroll; Brian R. Hirshman; Rushikesh Joshi; Parag Sanghvi; Clark C. Chen
Neuro-oncology | 2017
Ali A. Alattar
Neuro-oncology | 2016
Clark Chen; Ali A. Alattar; Alex Schupper; Michael G. Brandel; Jennifer Padwal; Brian R. Hirshman; Bob S. Carter